Phytoestrogens and breast cancer: In vitro anticancer activities of isoflavones, lignans, coumestans, stilbenes and their analogs and derivatives

Biomedicine and Pharmacotherapy

Volumn 107, Issue , 2018, Pages 1648-1666

  Basu, Paramita ^a   Maier, Camelia ^a  

^a TEXAS WOMAN'S UNIVERSITY   (United States)

Author keywords

Breast cancer; Estrogen; Phytoestrogen; Phytoestrogen analog; Phytoestrogen derivative

Indexed keywords

ANTINEOPLASTIC AGENT; COUMESTAN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOFLAVONE DERIVATIVE; LIGNAN DERIVATIVE; PHYTOESTROGEN; STILBENE DERIVATIVE; UNCLASSIFIED DRUG; ESTROGEN; ESTROGEN RECEPTOR;

AKT/MTOR SIGNALING; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE; CELL PROLIFERATION; DRUG MECHANISM; DRUG SYNTHESIS; EPIGENETICS; ESTROGEN SYNTHESIS; HISTONE MODIFICATION; HORMONE METABOLISM; HUMAN; IN VITRO STUDY; MAPK SIGNALING; METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; PI3K/AKT SIGNALING; PRIORITY JOURNAL; REVIEW; ANIMAL; BREAST TUMOR; CHEMISTRY; DRUG EFFECT; DRUG RESISTANCE; FEMALE; METABOLISM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ESTROGENS; FEMALE; HUMANS; PHYTOESTROGENS; RECEPTORS, ESTROGEN;

EID: 85053005776     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2018.08.100     Document Type: Review

References (206)

1. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. Cancer J. Clin. 61 (2011), 69–90.
2. Smith, R.A., Cokkinides, V., Brooks, D., Saslow, D., Shah, M., Brawley, O.W., Cancer screening in the United States, 2011: a review of current American Cancer society guidelines and issues in cancer screening. CA Cancer J. Clin. 61 (2011), 8–30.
3. de Kleijn, M.J., van der Schouw, Y.T., Wilson, P.W., Adlercreutz, H., Mazur, W., Grobbee, D.E., Jacques, P.F., Intake of dietary phytoestrogens is low in postmenopausal women in the United States: the Framingham study (1-4). J. Nutr. 131 (2001), 1826–1832.
4. Xiao, C.W., Health effects of soy protein and isoflavones in humans. J. Nutr. 138 (2008), 1244S–1249S.
5. Yeole, B.B., Trends in cancer incidence in female breast, cervix uteri, corpus uteri, and ovary in India, Asian Pac. J. Cancer Prev. 9 (2008), 119–122.
6. Mohite, V.R., Pratinidhi, A.K., Mohite, R.V., Reproductive risk factors and breast cancer: a case control study from rural India. Bangladesh J. Med. Sci. 14 (2015), 258–264.
7. Adlercreutz, H., Fotsis, T., Heikkinen, R., Dwyer, J.T., Woods, M., Goldin, B.R., Gorbach, S.L., Excretion of the lignans enterolactone and enterodiol and of equol in omnivorous and vegetarian postmenopausal women and in women with breast cancer. Lancet 2 (1982), 1295–1299.
8. Adlercreutz, H., Fotsis, T., Bannwart, C., Wähälä, K., Mäkelä, T., Brunow, G., Hase, T., Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens, in urine of women on various habitual diets. J. Steroid Biochem. 25 (1986), 791–797.
9. Adlercreutz, H., Honjo, H., Higashi, A., Fotsis, T., Hamalainen, E., Hasegawa, T., Okada, H., Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am. J. Clin. Nutr. 54 (1991), 1093–1100.
10. Adlercreutz, H., Markkanen, H., Watanabe, S., Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 342 (1993), 1209–1210.
11. Adlercreutz, C.H., Goldin, B.R., Gorbach, S.L., Höckerstedt, K.A., Watanabe, S., Hämäläinen, E.K., Markkanen, M.H., Mäkelä, T.H., Wähälä, K.T., Adlercreutz, T., Soybean phytoestrogen intake and cancer risk. J. Nutr. 125 (1995), 757S–770S.
12. Johnson, M.A., Maggiora, G.M., Concepts and Applications of Molecular Similarity. 1990, John Willey & Sons, New York.
13. Nikolova, N., Jaworska, J., Approaches to measure chemical similarity– a review. QSAR Comb. Sci. 22 (2003), 1006–1026.
14. Fulda, S., Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov. Today 15 (2010), 757–765.
15. Pan, M.H., Lin, C.L., Tsai, J.H., Ho, C.T., Chen, W.J., 3,5,3',4',5'-pentamethoxystilbene (MR-5), a synthetically methoxylated analogue of resveratrol, inhibits growth and induces G1 cell cycle arrest of human breast carcinoma MCF-7 cells. J. Agric. Food Chem. 58 (2010), 226–234.
16. Murias, M., Luczak, M.W., Niepsuj, A., Krajka-Kuzniak, V., Zielinska-Przyjemska, M., Jagodzinski, P.P., Jäger, W., Szekeres, T., Jodynis-Liebert, J., Cytotoxic activity of 3,3′,4,4′,5,5′-hexahydroxystilbene against breast cancer cells is mediated by induction of p53 and downregulation of mitochondrial superoxide dismutase. Toxicol. Vitr. 22 (2008), 1361–1370.
17. Lai, F., Liu, Q., Liu, X., Ji, M., Xie, P., Chen, X., LXY6090 – a novel manassantin a derivative – limits breast cancer growth through hypoxia-inducible factor-1 inhibition. Onco. Targets Ther. 9 (2016), 3829–3840.
18. Marik, R., Allu, M., Anchoori, R., Stearns, V., Umbricht, C.B., Khan, S., Potent genistein derivatives as inhibitors of estrogen receptor alpha-positive breast cancer. Cancer Biol. Ther. 11 (2011), 883–892.
19. Grande, F., Rizzuti, B., Occhiuzzi, M.A., Ioele, G., Casacchia, T., Gelmini, F., Guzzi, R., Garofalo, A., Statti, G., Identification by molecular docking of homoisoflavones from Leopoldia comosa as ligands of estrogen receptors. Molecules, 23, 2018, E894, 10.3390/molecules23040894.
20. Chi, F., Wu, R., Zeng, Y.C., Xing, R., Liu, Y., Xu, Z.G., Post-diagnosis Soy food intake and breast cancer survival: a meta-analysis of cohort studies. Asian Pac. J. Cancer Prev. 14 (2013), 2407–2412.
21. Guha, N., Kwan, M.L., Quesenberry, C.P., Weltzien, E.K., Castillo, A.L., Caan, B.J., Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the life after cancer epidemiology study. Breast Cancer Res. Treat. 118 (2009), 395–405.
22. Shu, X.O., Zheng, Y., Cai, H., Gu, K., Chen, Z., Zheng, W., Lu, W., Soy food intake and breast cancer survival. JAMA 302 (2009), 2437–2443.
23. Verheus, M., van Gils, C.H., Keinan-Boker, L., Grace, P.B., Bingham, S.A., Peeters, P.H., Plasma phytoestrogens and subsequent breast cancer risk. J. Clin. Oncol. 25 (2007), 648–655.
24. Wu, A.H., Yu, M.C., Tseng, C.C., Pike, M.C., Epidemiology of soy exposures and breast cancer risk. Br. J. Cancer 98 (2008), 9–14.
25. Dixon, R.A., Phytoestrogens. Annu. Rev. Plant Biol. 55 (2004), 225–261.
26. Michel, T., Halabalaki, M., Skaltsounis, A.L., New concepts, experimental approaches, and dereplication strategies for the discovery of novel phytoestrogens from natural sources. Planta Med. 79 (2013), 514–532.
27. Lissin, L.W., Cooke, J.P., Phytoestrogens and cardiovascular health. J. Am. Coll. Cardiol. 35 (2000), 1403–1410.
28. Pike, A.C., Brzozowski, A.M., Hubbard, R.E., Bonn, T., Thorsell, A.G., Engström, O., Ljunggren, J., Gustafsson, J.A., Carlquist, M., Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 18 (1999), 4608–4618.
29. Ferrer, J.L., Austin, M.B., Stewart, C., Noel, J.P., Structure and function of enzymes involved in the biosynthesis of phenylpropanoids. Plant Physiol. Biochem. 46 (2008), 356–370.
30. Kašparová, M., Phytoestrogens from red clover. Prakt. Lék. 9 (2013), 201–203.
31. Schmitt, E., Lehmann, L., Metzler, M., Stopper, H., Hormonal and genotoxic activity of resveratrol. Toxicol. Lett. 136 (2002), 133–142.
32. Ford, J.D., Huang, K.S., Wang, H.B., Davin, L.B., Lewis, N.G., Biosynthetic pathway to the cancer chemopreventive secoisolariciresinol diglucoside-hydroxymethylglutaryl ester-linked lignan oligomers in flax seeds (Linum usitatissimum). J. Nat. Prod. 64 (2001), 1388–1397.
33. Dixon, R.A., Sankawa, U., (eds.) Isoflavonoids: Biochemistry, Molecular Biology and Biological Functions, in Comprehensive Natural Products Chemistry, 1999, Elsevier, Oxford, 773–823.
34. Berlin, J., Dewick, P.M., Barz, W., Grisebach, H., Biosynthesis of coumestrol in Phaseolus aureus. Phytochemistry 11 (1972), 1689–1693.
35. Dewick, P.M., Braz, W., Grisebach, H., Biosynthesis of coumestrol in Phaseolus aureus. Phytochemistry 9 (1970), 775–783.
36. Schroder, J., Schroder, G., Stilbene and chalcone synthases: related enzymes with key functions in plant-specific pathways. Z. Naturforsch. C 45 (1990), 1–8.
37. Turner, J.V., Agatonovic-Kustrin, S., Glass, B.D., Molecular aspects of phytoestrogen selective binding at estrogen receptors. J. Pharm. Sci. 96 (2007), 1879–1885.
38. Fitzpatrick, L.A., Phytoestrogens—mechanism of action and effect on bone markers and bone mineral density. Endocrinol. Metab. Clin. North Am. 32 (2003), 233–252.
39. Soto, A.M., Sonnenschein, C., Chung, K.L., Fernandez, M.F., Olea, N., Serrano, F.O., The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. Environ. Health Perspect. 103 (1995), 113–122.
40. Mueller, S.O., Simon, S., Chae, K., Metzler, M., Korach, K.S., Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol. Sci. 80 (2004), 14–25.
41. Tremblay, G.B., Giguère, V., Coregulators of estrogen receptor action. Crit. Rev. Eukaryot. Gene Expr. 12 (2002), 1–22.
42. An, J., Tzagarakis-Foster, C., Scharschmidt, T.C., Lomri, N., Leitman, D.C., Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J. Biol. Chem. 276 (2001), 17808–17814.
43. Nishikawa, J., Saito, K., Goto, J., Dakeyama, F., Matsuo, M., Nishihara, T., New screening methods for chemicals with hormonal activities using interaction of nuclear hormone receptor with coactivator. Toxicol. Appl. Pharmacol. 154 (1999), 76–83.
44. Routledge, E.J., White, R., Parker, M.G., Sumpter, J.P., Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ERbeta. J. Biol. Chem. 275 (2000), 35986–35993.
45. Ise, R., Han, D., Takahashi, Y., Terasaka, S., Inoue, A., Tanji, M., Kiyama, R., Expression profiling of the estrogen responsive genes in response to phytoestrogens using a customized DNA microarray. FEBS Lett. 579 (2005), 1732–1740.
46. Ziegler, R.G., Phytoestrogens and breast cancer. Am. J. Clin. Nutr. 79 (2004), 183–184.
47. Setchell, K.D., Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am. J. Clin. Nutr. 68 (1998), 1333S–1346S.
48. Muir, A.D., Westcott, N.D., Flaxseed constituents and human health. Muir, A.D., Westcott, N.D., (eds.) Flax: the Genus Linum, 2003, Taylor & Francis, London, 243–251.
49. Ho, H.M., Chen, R.Y., Leung, L.K., Chan, F.L., Huang, Y., Chen, Z.Y., Difference in flavonoid and isoflavone profile between soybean and soy leaf. Biomed. Pharmacother. 56 (2002), 289–295.
50. Reinli, K., Block, G., Phytoestrogen content of foods–a compendium of literature values. Nutr. Cancer 26 (1996), 123–148.
51. Zaheer, K., Humayoun Akhtar, M., An updated review of dietary isoflavones: nutrition, processing, bioavailability and impacts on human health. Crit. Rev. Food Sci. Nutr. 57 (2017), 1280–1293.
52. Kuhnle, G.G., Dell'Aquila, C., Aspinall, S.M., Runswick, S.A., Mulligan, A.A., Bingham, S.A., Phytoestrogen content of cereals and cereal-based foods consumed in the UK. Nutr. Cancer 61 (2009), 302–309.
53. Mazur, W., Fotsis, T., Wähälä, K., Ojala, S., Salakka, A., Adlercreutz, H., Isotope dilution gas chromatographic-mass spectrometric method for the determination of isoflavonoids, coumestrol, and lignans in food samples. Anal. Biochem. 233 (1996), 169–180.
54. Mazur, W.M., Duke, J.A., Wähälä, K., Rasku, S., Adlercreutz, H., Isoflavonoids and lignans in legumes: nutritional and health aspects in humans. J. Nutr. Biochem. 9 (1998), 193–200.
55. Milder, I.E., Arts, I.C., van de Putte, B., Venema, D.P., Hollman, P.C., Lignan contents of Dutch plant foods: a database including lariciresinol, pinoresinol, secoisolariciresinol and matairesinol. Br. J. Nutr. 93 (2005), 393–402.
56. Peñalvo, J.L., Adlercreutz, H., Uehara, M., Ristimaki, A., Watanabe, S., Lignan content of selected foods from Japan. J. Agric. Food Chem. 56 (2008), 401–409.
57. Smeds, A.I., Willför, S.M., Pietarinen, S.P., Peltonen-Sainio, P., Reunanen, M.H., Occurrence of “mammalian” lignans in plant and water sources. Planta 226 (2007), 639–646.
58. Thompson, L.U., Boucher, B.A., Liu, Z., Cotterchio, M., Kreiger, N., Phytoestrogen content of foods consumed in Canada, including isoflavones, lignans, and coumestan. Nutr. Cancer 54 (2006), 184–201.
59. Zamora-Ros, R., Knaze, V., Luján-Barroso, L., Kuhnle, G.G., Mulligan, A.A., Touillaud, M., Slimani, N., Romieu, I., Powell, N., Tumino, R., Peeters, P.H., de Magistris, M.S., Ricceri, F., Sonestedt, E., Drake, I., Hjartåker, A., Skie, G., Mouw, T., Wark, P.A., Romaguera, D., Bueno-de-Mesquita, H.B., Ros, M., Molina, E., Sieri, S., Quirós, J.R., Huerta, J.M., Tjønneland, A., Halkjær, J., Masala, G., Teucher, B., Kaas, R., Travis, R.C., Dilis, V., Benetou, V., Trichopoulou, A., Amiano, P., Ardanaz, E., Boeing, H., Förster, J., Clavel-Chapelon, F., Fagherazzi, G., Perquier, F., Johansson, G., Johansson, I., Cassidy, A., Overvad, K., González, C.A., Dietary intakes and food sources of phytoestrogens in the European Prospective Investigation into Cancer and Nutrition (EPIC) 24-hour dietary recall cohort. Eur. J. Clin. Nutr. 66 (2012), 932–941.
60. Patisaul, H.B., Jefferson, W., The pros and cons of phytoestrogens. Front. Neuroendocrinol. 31 (2010), 400–419.
61. Burns, J., Yokota, T., Ashihara, H., Lean, M.E., Crozier, A., Plant foods and herbal sources of resveratrol. J. Agric. Food Chem. 50 (2002), 3337–3340.
62. Lecomte, S., Demay, F., Ferrière, F., Pakdel, F., Phytochemicals targeting estrogen receptors: beneficial rather than adverse effects?. Int. J. Mol. Sci., 18, 2017, E1381.
63. Maskarinec, G., Takata, Y., Franke, A.A., Williams, A.E., Murphy, S.P., A 2-year soy intervention in premenopausal women does not change mammographic densities. J.Nutr. 134 (2004), 3089–3094.
64. Long, B.J., Jelovac, D., Handratta, V., Thiantanawat, A., MacPherson, N., Ragaz, J., Goloubeva, O.G., Brodie, A.M., Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J. Natl. Cancer Inst. 96 (2004), 456–465.
65. Ju, Y.H., Doerge, D.R., Woodling, K.A., Hartman, J.A., Kwak, J., Helferich, W.G., Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis 29 (2008), 2162–2168.
66. Lang, L., Liu, X., Li, Y., Zhou, Q., Xie, P., Yan, C., Chen, X., A synthetic manassantin a derivative inhibits hypoxia-inducible factor 1 and tumor growth. PLoS One, 9, 2014, e99584, 10.1371/journal.pone.0099584.
67. Stivala, L.A., Savio, M., Carafoli, F., Perucca, P., Bianchi, L., Maga, G., Forti, L., Pagnoni, U.M., Albini, A., Prosperi, E., Vannini, V., Specific structural determinants are responsible for the antioxidant activity and the ell cycle effects of resveratrol. J. Biol. Chem. 276 (2001), 22586–22594.
68. Lee, S.K., Nam, K.A., Hoe, Y.H., Min, H.Y., Kim, E.Y., Ko, H., Song, S., Lee, T., Kim, S., Synthesis and evaluation of cytotoxicity of stilbene analogues. Arch. Pharm. Res. 26 (2003), 253–257.
69. Lappano, R., Rosano, C., Madeo, A., Albanito, L., Plastina, P., Gabriele, B., Forti, L., Stivala, L.A., D, Iacopetta, Dolce, V., Andò, S., Pezzi, V., Maggiolini, M., Structure-activity relationships of resveratrol and derivatives in breast cancer cells. Mol. Nutr. Food Res. 53 (2009), 845–858.
70. Vermeulen, K., Van Bockstaele, D.R., Berneman, Z.N., The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36 (2003), 131–149.
71. Tobin, N.P., Bergh, J., Analysis of cyclin D1 in breast cancer: a call to arms. Curr. Breast Cancer Rep. 4 (2012), 171–173.
72. Musgrove, E.A., Lee, C.S., Buckley, M.F., Sutherland, R.L., Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc. Natl. Acad. Sci. 91 (1994), 8022–8026.
73. Sherr, C.J., G1 phase progression: cycling on cue. Cell. 79 (1994), 551–555.
74. Ohtsubo, M., Theodoras, A.M., Schumacher, J., Roberts, J.M., Pagano, M., Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol. Cell Biol. 15 (1995), 2612–2624.
75. Girard, F., U, Strausfeld, Fernandez, A., Lamb, N.J., Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 67 (1991), 1169–1179.
76. Walker, D.H., Maller, J.L., Role for cyclin A in the dependence of mitosis on completion of DNA replication. Nature. 354 (1991), 314–317.
77. Coverley, D., Laman, H., Laskey, R.A., Distinct roles for cyclins E and A during DNA replication complex assembly and activation. Nat. Cell Biol. 4 (2002), 523–528.
78. Arellano, M., Moreno, S., Regulation of CDK/cyclin complexes during the cell cycle. Int. J. Biochem. Cell Biol. 29 (1997), 559–573.
79. King, R.W., Jackson, P.K., Kirschner, M.W., Mitosis in transition. Cell. 79 (1994), 563–571.
80. Ronghe, A., Chatterjee, A., Singh, B., Dandawate, P., Murphy, L., Bhat, N.K., Padhye, S., Bhat, H.K., Differential regulation of estrogen receptors α and β by 4-(E)-{(4-hydroxyphenylimino)-methylbenzene,1,2-diol}, a novel resveratrol analog. J. Steroid Biochem. Mol. Biol. 144 (2014), 500–512.
81. Ronghe, A., Chatterjee, A., Singh, B., Dandawate, P., Abdalla, F., Bhat, N.K., Padhye, S., Bhat, H.K., 4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, 1 a novel resveratrol analog, differentially regulates estrogen receptors α and β in breast cancer cells. Toxicol. Appl. Pharmacol. 301 (2016), 1–13.
82. Ma, Z., Molavi, O., Haddadi, A., Lai, R., Gossage, R.A., Lavasanifar, A., Resveratrol analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol. Cancer Chemother. Pharmacol. 63 (2008), 27–35.
83. Wang, Y., Ding, L., Wang, X., Zhang, J., Han, W., Feng, L., Sun, J., Jin, H., Wang, X.J., Pterostilbene simultaneously induces apoptosis, cell cycle arrest and cyto-protective autophagy in breast cancer cells. Am. J. Transl. Res. 4 (2012), 44–51.
84. Chen, J., Zeng, J., Xin, M., Huang, W., Chen, X., Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo. Horm. Metab. Res. 43 (2011), 681–686.
85. Choi, E.J., Kim, G.H., Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB-453 cells. Phytomedicine 15 (2008), 683–690.
86. Zafar, A., Singh, S., Naseem, I., Cytotoxic activity of soy phytoestrogen coumestrol against human breast cancer MCF-7 cells: insights into the molecular mechanism. Food Chem. Toxicol. 99 (2017), 149–161.
87. Foster, J.S., Henley, D.C., Ahamed, S., Wimalasena, J., Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol. Metab. 12 (2001), 320–327.
88. Sherr, C.J., Roberts, J.M., Inhibitors of mammalian cyclin-dependent kinases. Genes Dev. 9 (1995), 1149–1163.
89. Polyak, K., Lee, M.H., Erdjument-Bromage, H., Koff, A., Roberts, J.M., Tempst, P., Massagué, J., Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78 (1994), 59–66.
90. Harper, J.W., Elledge, S.J., Keyomarsi, K., Dynlacht, B., Tsai, L.H., Zhang, P., Dobrowolski, S., Bai, C., Connell-Crowley, L., Swindell, E., Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell 6 (1995), 387–400.
91. Lee, M.H., Reynisdóttir, I., Massagué, J., Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9 (1995), 639–649.
92. Hengst, L., Reed, S.I., Inhibitors of the Cip /Kip family. Curr. Top. Microbiol. Immunol. 227 (1998), 25–41.
93. Seo, H.S., Choi, H.S., Choi, H.S., Choi, Y.K., Um, J.Y., Choi, I., Shin, Y.C., Ko, S.G., Phytoestrogens induce apoptosis via extrinsic pathway, inhibiting nuclear factor-κB signaling in HER2-overexpressing breast cancer cells. Anticancer Res. 31 (2011), 3301–3313.
94. Shyur, L.F., Lee, S.H., Chang, S.T., Lo, C.P., Kuo, Y.H., Wang, S.Y., Taiwanin A inhibits MCF-7 cancer cell activity through induction of oxidative stress, upregulation of DNA damage checkpoint kinases, and activation of p53 and FasL/Fas signaling pathways. Phytomedicine 18 (2010), 16–24.
95. Prietsch, R.F., Monte, L.G., Da Silva, F.A., Beira, F.T., Del Pino, F.A., Campos, V.F., Collares, T., Pinto, L.S., Spanevello, R.M., Gamaro, G.D., Braganhol, E., Genistein induces apoptosis and autophagy in human breast MCF-7 cells by modulating the expression of proapoptotic factors and oxidative stress enzymes. Mol. Cell. Biochem. 390 (2014), 235–242.
96. Hong, Y.B., Kang, H.J., Kim, H.J., Rosen, E.M., Dakshanamurthy, S., Rondanin, R., Baruchello, R., Grisolia, G., Daniele, S., Bae, I., Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cells. Exp. Mol. Med. 41 (2009), 151–160.
97. Kim, J.A., Kim, D.H., Hossain, M.A., Kim, M.Y., Sung, B., Yoon, J.H., Suh, H., Jeong, T.C., Chung, H.Y., Kim, N.D., HS-1793, a resveratrol analogue, induces cell cycle arrest and apoptotic cell death in human breast cancer cells. Int. J. Oncol. 44 (2014), 473–480.
98. Chelsky, Z.L., Yue, P., Kondratyuk, T.P., Paladino, D., Pezzuto, J.M., Cushman, M., Turkson, J., A Resveratrol analogue promotes ERKMAPK-dependent Stat3 serine and tyrosine phosphorylation alterations and antitumor effects in vitro against human tumor cells. Mol. Pharmacol. 88 (2015), 524–533.
99. Peterson, J.A., Doughty, H.P., Eells, A.J., Johnson, T.A., Hastings, J.P., Crowther, C.M., Andrus, M.B., Kenealey, J.D., The effects of 4’-esterified resveratrol derivatives on calcium dynamics in breast cancer cells. Molecules, 22, 2017, e1968, 10.3390/molecules22111968.
100. Chen, J., Ge, B., Wang, Y., Ye, Y., Zeng, S., Huang, Z., Biochanin a promotes proliferation that involves a feedback loop of microRNA-375 and estrogen receptor alpha in breast cancer cells. Cell. Physiol. Biochem. 35 (2015), 639–646.
101. Choi, E.J., Kim, G.H., O-desmethylangolensin inhibits the proliferation of human breast cancer MCF7 cells by inducing apoptosis and promoting cell cycle arrest. Oncol. Lett. 6 (2013), 1784–1788.
102. Mar, W., Je, K.H., Seo, E.K., Cytotoxic constituents of Psoralea corylifolia. Arch. Pharm. Res. 24 (2001), 211–213.
103. Taghizadeh, B., Ghavami, L., Nikoofar, A., Goliaei, B., Equol as a potent radiosensitizer in estrogen receptor-positive and -negative human breast cancer cell lines. Breast Cancer 22 (2015), 382–390.
104. Wu, X.Y., Xu, H., Wu, Z.F., Chen, C., Liu, J.Y., Wu, G.N., Yao, X.Q., Liu, F.K., Li, G., Shen, L., Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. Oncotarget 6 (2015), 44563–44578.
105. Maggiolini, M., Vivacqua, A., Fasanella, G., Recchia, A.G., Sisci, D., Pezzi, V., Montanaro, D., Musti, A.M., Picard, D., Andò, S., The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17β-estradiol and phytoestrogens in breast cancer cells. J. Biol. Chem. 279 (2004), 27008–27016.
106. Parrish, A.B., Freel, C.D., Kornbluth, S., Cellular mechanisms controlling caspase activation and function. Cold Spring Harb. Perspect. Biol., 5, 2013, 10.1101/cshperspect.a008672.
107. Shi, Y., Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell 9 (2002), 459–470.
108. Elmore, S., Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35 (2007), 495–516.
109. Park, Y.J., Choi, C.I., Chung, K.H., Kim, K.H., Pharbilignan C induces apoptosis through a mitochondria-mediated intrinsic pathway in human breast cancer cells. Bioorg. Med. Chem. Lett. 26 (2016), 4645–4649.
110. Chen, F.P., Chien, M.H., Phytoestrogens induce apoptosis through a mitochondria/caspase pathway in human breast cancer cells. Climacteric 17 (2014), 385–392.
111. Jin, S., Zhang, Q.Y., Kang, X.M., Wang, J.X., Zhao, W.H., Daidzein induces MCF-7 breast cancer cell apoptosis via the mitochondrial pathway. Ann. Oncol. 21 (2010), 263–268.
112. Aiyar, S.E., Park, H., Aldo, P.B., Mor, G., Gildea, J.J., Miller, A.L., Thompson, E.B., Castle, J.D., Kim, S., Santen, R.J., TMS, a chemically modified herbal derivative of Resveratrol, induces cell death by targeting Bax. Breast Cancer Res. Treat. 124 (2010), 265–277.
113. Feng, T., Cao, W., Shen, W., Zhang, L., Gu, X., Guo, Y., Tsai, H.I., Liu, X., Li, J., Zhang, J., Li, S., Wu, F., Liu, Y., Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy. Oncotarget 8 (2017), 329–344.
114. Charalambous, C., Pitta, C.A., Constantinou, A.I., Equol enhances tamoxifen's anti-tumor activity by induction of caspase-mediated apoptosis in MCF-7 breast cancer cells. BMC Cancer, 13, 2013, 238, 10.1186/1471-2407-13-238.
115. Nikhil, K., Sharan, S., Singh, A.K., Chakraborty, A., Roy, P., Anticancer activities of pterostilbene-isothiocyanate conjugate in breast cancer cells: involvement of PPARγ. PLoS One, 9, 2014, e104592, 10.1371/journal.pone.0104592.
116. Moon, D., McCormack, D., McDonald, D., McFadden, D., Pterostilbene induces mitochondrially derived apoptosis in breast cancer cells in vitro. J. Surg. Res. 180 (2013), 208–215.
117. Ono, M., Ejima, K., Higuchi, T., Takeshima, M., Wakimoto, R., Nakano, S., Equol enhances apoptosis-inducing activity of genistein by increasing Bax/Bcl-xL expression ratio in MCF-7 human breast cancer cells. Nutr. Cancer 69 (2017), 1300–1307.
118. Zafar, A., Singh, S., Satija, Y.K., Saluja, D., Naseem, I., Deciphering the molecular mechanism underlying anticancer activity of coumestrol in triple-negative breast cancer cells. Toxicol. In Vitro 46 (2018), 19–28.
119. Zhao, E., Mu, Q., Phytoestrogen biological actions on mammalian reproductive system and cancer growth. Sci. Pharm. 79 (2011), 1–20.
120. Xiao, G., Fu, J., NF-κB and cancer: a paradigm of Yin-Yang. Am. J. Cancer Res. 1 (2011), 192–221.
121. Zhou, Y., Eppenberger-Castori, S., Marx, C., Yau, C., Scott, G.K., Eppenberger, U., Benz, C.C., Activation of nuclear factor-κB (NFκB) identifies a high-risk subset of hormone-dependent breast cancers. Int. J. Biochem. Cell Biol. 37 (2005), 1130–1144.
122. Pahl, H.L., Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 18 (1999), 6853–6866.
123. Pan, H., Zhou, W., He, W., Liu, X., Ding, Q., Ling, L., Zha, X., Wang, S., Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-κB activity via the Notch-1 pathway. Int. J. Mol. Med. 30 (2012), 337–343.
124. Maxwell, T., Chun, S.Y., Lee, K.S., Kim, S., Nam, K.S., The anti-metastatic effects of the phytoestrogen arctigenin on human breast cancer cell lines regardless of the status of ER expression. Int. J. Oncol. 50 (2017), 727–735.
125. Ciruelos Gil, E.M., Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat. Rev. 40 (2014), 862–871.
126. López-Knowles, E., O'toole, S.A., Mcneil, C.M., Millar, E.K., Qiu, M.R., Crea, P., Daly, R.J., Musgrove, E.A., Sutherland, R.L., PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int. J. Cancer 126 (2010), 1121–1131.
127. Vivanco, I., Sawyers, C.L., The phosphatidylinositol 3-Kinase-AKT pathway in human cancer. Nat. Rev. Cancer 2 (2002), 489–501.
128. Zhao, L., Vogt, P.K., Class I PI3K in oncogenic cellular transformation. Oncogene 27 (2008), 5486–5496.
129. Serrano, M.L., Sánchez-Gómez, M., Bravo, M.M., Yakar, S., Leroith, D., Differential expression of IGF-I and insulin receptor isoforms in HPV positive and negative human cervical cancer cell lines. Horm. Metab. Res. 40 (2008), 661–667.
130. Chen, J., Hou, R., Zhang, X., Ye, Y., Wang, Y., Tian, J., Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways. PLoS One, 9, 2014, e91245, 10.1371/journal.pone.0091245.
131. Zhou, R., Xu, L., Ye, M., Liao, M., Du, H., Chen, H., Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways. Horm. Metab. Res. 46 (2014), 753–760.
132. Tsai, J.H., Hsu, L.S., Lin, C.L., Hong, H.M., Pan, M.H., Way, T.D., W.J. Chen, 3,5,4’-trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition. Toxicol. Appl. Pharmacol. 272 (2013), 746–756.
133. Sun, J.Q., Zhang, G.L., Zhang, Y., Nan, N., Sun, X., Yu, M.W., Wang, H., Li, J.P., Wang, X.M., Spatholobus suberectus column extract inhibits estrogen receptor positive breast cancer via suppressing ER MAPK PI3K/AKT pathway. Evid. Based Complement. Alternat. Med., 2016, 2934340, 10.1155/2016/2934340 2016.
134. de la Parra, C., Castillo-Pichardo, L., Cruz-Collazo, A., Cubano, L., Redis, R., Calin, G.A., Dharmawardhane, S., Soy isoflavone genistein-mediated downregulation of miR-155 contributes to the anticancer effects of genistein. Nutr. Cancer 68 (2016), 154–164.
135. Waite, K.A., Sinden, M.R., Eng, C., Phytoestrogen exposure elevates PTEN levels. Hum. Mol. Genet. 14 (2005), 1457–1463.
136. Saini, K.S., Loi, S., de Azambuja, E., Metzger-Filho, O., Saini, M.L., Ignatiadis, M., Dancey, J.E., Piccart-Gebhart, M.J., Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat. Rev. 39 (2013), 935–946.
137. Bulavin, D.V., Fornace, A.J., p38 MAP kinase's emerging role as a tumor suppressor. Adv. Cancer Res. 92 (2004), 95–118.
138. Dhillon, A.S., Hagan, S., Rath, O., Kolch, W., MAP kinase signalling pathways in cancer. Oncogene 26 (2007), 3279–3290.
139. Hsieh, C.J., Kuo, P.L., Hsu, Y.C., Huang, Y.F., Tsai, E.M., Hsu, Y.L., Arctigenin, a dietary phytoestrogen, induces apoptosis of estrogen receptor-negative breast cancer cells through the ROS/p38 MAPK pathway and epigenetic regulation. Free Radic. Biol. Med. 67 (2014), 159–170.
140. Li, Z., Li, J., Mo, B., Hu, C., Liu, H., Qi, H., Wang, X., Xu, J., Genistein induces cell apoptosis in MDA-MB-231 breast cancer cells via the mitogen-activated protein kinase pathway. Toxicol. In Vitro 22 (2008), 1749–1753.
141. Brisken, C., O'Malley, B., Hormone action in the mammary gland. Cold Spring Harb. Perspect. Biol., 2, 2010, a003178, 10.1101/cshperspect.a003178.
142. Clarke, R.B., Steroid receptors and proliferation in the human breast. Steroids 68 (2003), 789–794.
143. Mak, P., Leung, Y.K., Tang, W.Y., Harwood, C., Ho, S.M., Apigenin suppresses cancer cell growth through ERβ. Neoplasia 8 (2006), 896–904.
144. Morito, K., Hirose, T., Kinjo, J., Hirakawa, T., Okawa, M., Nohara, T., Ogawa, S., Inoue, S., Muramatsu, M., Masamune, Y., Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol. Pharm. Bull. 24 (2001), 351–356.
145. Sotoca, A.M., Ratman, D., van der Saag, P., Ström, A., Gustafsson, J.A., Vervoort, J., Rietjens, I.M., Murk, A.J., Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells depends on the ERα/ERβ ratio. J. Steroid Biochem. Mol. Biol. 112 (2008), 171–178.
146. Russo, M., Russo, G.L., Daglia, M., Kasi, P.D., Ravi, S., Nabavi, S.F., Nabavi, S.M., Understanding genistein in cancer: the “good” and the “bad” effects: a review. Food Chem. 196 (2016), 589–600.
147. Kuiper, G.G., Lemmen, J.G., Carlsson, B., Corton, J.C., Safe, S.H., van der Saag, P.T., van der Burg, B., Gustafsson, J.A., Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139 (1998), 4252–4263.
148. Obiorah, I.E., Fan, P., Jordan, V.C., Breast cancer cell apoptosis with phytoestrogens is dependent on an estrogen-deprived state. Cancer Prev. Res. (Phila) 7 (2014), 939–949.
149. Jakowlew, S.B., Breathnach, R., Jeltsch, J.M., Masiakowski, P., Chambon, P., Sequence of the ps2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acids Res. 12 (1984), 2861–2878.
150. Skliris, G.P., Lewis, A., Emberley, E., Peng, B., Weebadda, W.K., Kemp, A., Davie, J.R., Shiu, R.P., Watson, P.H., Murphy, L.C., Estrogen receptor-beta regulates psoriasin (S100A7) in human breast cancer. Breast Cancer Res. Treat. 104 (2007), 75–85.
151. Jiang, Y., Gong, P., Madak-Erdogan, Z., Martin, T., Jeyakumar, M., Carlson, K., Khan, I., Smillie, T.J., Chittiboyina, A.G., Rotte, S.C., Helferich, W.G., Katzenellenbogen, J.A., Katzenellenbogen, B.S., Mechanisms enforcing the estrogen receptor β selectivity of botanical estrogens. FASEB J. 27 (2013), 4406–4418.
152. Gojis, O., Rudraraju, B., Gudi, M., Hogben, K., Sousha, S., Coombes, R.C., Cleator, S., Palmieri, C., The role of SRC-3 in human breast cancer. Nat. Rev. Clin. Oncol. 7 (2010), 83–89.
153. Chen, J., Zhao, X., Ye, Y., Wang, Y., Tian, J., Estrogen receptor beta-mediated proliferative inhibition and apoptosis in human breast cancer by calycosin and formononetin. Cell. Physiol. Biochem. 32 (2013), 1790–1797.
154. Zafar, A., Ahmad, S., Naseem, I., Insight into the structural stability of coumestrol with human estrogen receptor α and β subtypes: a combined approach involving docking and molecular dynamics simulation studies. RSC Adv. 5 (2015), 81295–81312.
155. Bai, Z., Gust, R., Breast cancer, estrogen receptor and ligands. Arch. Pharm. (Weinheim). 342 (2009), 133–149.
156. Miller, W.R., Aromatase and the breast: regulation and clinical aspects. Maturitas 54 (2006), 335–341.
157. Rice, S., Whitehead, S.A., Phytoestrogens and breast cancer - Promoters or protectors?. Endocr. Relat. Cancer 13 (2006), 995–1015.
158. Lephart, E.D., Modulation of aromatase by phytoestrogens. Enzyme Res., 2015, 594656, 10.1155/2015/594656 2015.
159. Wang, Y., Man Gho, W., Chan, F.L., Chen, S., Leung, L.K., The red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression. Br. J. Nutr. 99 (2008), 303–310.
160. Chen, S., Zhou, D., Okubo, T., Kao, Y.C., Yang, C., Breast tumor aromatase: functional role and transcriptional regulation. Endocr. Relat. Cancer 6 (1999), 149–156.
161. Licznerska, B., Szaefer, H., Wierzchowski, M., Mikstacka, R., Papierska, K., Baer-Dubowska, W., Evaluation of the effect of the new methoxy-stilbenes on expression of receptors and enzymes involved in estrogen synthesis in cancer breast cells. Mol. Cell. Biochem. 444 (2018), 53–62.
162. Michiels, P.J.A., Ludwig, C., Stephan, M., Fischer, C., Möller, G., Messinger, J., van Dongen, M., Thole, H., Adamski, J., Günther, U.L., Ligand-based NMR spectra demonstrate an additional phytoestrogen binding site for 17β-hydroxysteroid dehydrogenase type 1. J. Steroid Biochem. Mol. Biol. 117 (2009), 93–98.
163. Tsuchiya, Y., Nakajima, M., Yokoi, T., Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 227 (2005), 115–124.
164. Feng, S., Cao, Z., Wang, X., Role of aryl hydrocarbon receptor in cancer. Biochim. Biophys. Acta 1836 (2013), 197–210.
165. MacPherson, L., Matthews, J., Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor α expression in human breast cancer cells. Cancer Lett. 299 (2010), 119–129.
166. Han, E.H., Kim, J.Y., Jeong, H.G., Effect of biochanin A on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells. Arch. Pharm. Res. 29 (2006), 570–576.
167. Atherton, K.M., Mutch, E., Ford, D., Metabolism of the soyabean isoflavone daidzein by CYP1A2 and the extra-hepatic CYPs 1A1 and 1B1 affects biological activity. Biochem. Pharmacol. 72 (2006), 624–631.
168. Huang, Y., Nayak, S., Jankowitz, R., Davidson, N.E., Oesterreich, S., Epigenetics in breast cancer: what's new?. Breast Cancer Res., 13, 2011, 225.
169. Bosviel, R., Dumollard, E., Déchelotte, P., Bignon, Y.J., Bernard-Gallon, D., Can soy phytoestrogens decrease DNA methylation in BRCA1 and BRCA2 oncosuppressor genes in breast cancer?. OMICS 16 (2012), 235–244.
170. Bosviel, R., Durif, J., Déchelotte, P., Bignon, Y.J., Bernard-Gallon, D., Epigenetic modulation of BRCA1 and BRCA2 gene expression by equol in breast cancer cell lines. Br. J. Nutr. 108 (2012), 1187–1193.
171. Xie, Q., Bai, Q., Zou, L.Y., Zhang, Q.Y., Zhou, Y., Chang, H., Yi, L., Zhu, J.D., Mi, M.T., Genistein inhibits DNA methylation and increases expression of tumor suppressor genes in human breast cancer cells. Genes Chromosomes Cancer 53 (2014), 422–431.
172. Paluszczak, J., Krajka-Kuźniak, V., Baer-Dubowska, W., The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicol. Lett. 192 (2010), 119–125.
173. Kala, R., Tollefsbol, T.O., A novel combinatorial epigenetic therapy using resveratrol and pterostilbene for restoring estrogen receptor-α (ERα) expression in ERα-negative breast cancer cells. PLoS One, 11, 2016, e0155057, 10.1371/journal.pone.0155057.
174. Khan, S.I., Aumsuwan, P., Khan, I.A., Walker, L.A., Dasmahapatra, A.K., Epigenetic events associated with breast cancer and their prevention by dietary components targeting the epigenome. Chem. Res. Toxicol. 25 (2012), 61–73.
175. Mirza, S., Sharma, G., Parshad, R., Gupta, S.D., Pandya, P., Ralhan, R., Expression of DNA methyltransferases in breast cancer patients and to analyze the effect of natural compounds on DNA methyltransferases and associated proteins. J. Breast Cancer 16 (2013), 23–31.
176. Rice, J.C., Allis, C.D., Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr. Opin. Cell Biol. 13 (2001), 263–273.
177. Frolov, M.V., Dyson, N.J., Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J. Cell. Sci. 117 (2004), 2173–2181.
178. Prokhortchouk, E., Hendrich, B., Methyl-CpG binding proteins and cancer: are MeCpGs more important than MBDs?. Oncogene 21 (2002), 5394–5399.
179. Avci, C.B., Susluer, S.Y., Caglar, H.O., Balci, T., Aygunes, D., Dodurga, Y., Gunduz, C., Genistein-induced mir-23b expression inhibits the growth of breast cancer cells. Contemp. Oncol. (Pozn) 19 (2015), 32–35.
180. Pellegrino, L., Stebbing, J., Braga, V.M., Frampton, A.E., Jacob, J., Buluwela, L., Jiao, L.R., Periyasamy, M., Madsen, C.D., Caley, M.P., Ottaviani, S., Roca-Alonso, L., EI-Bahrawy, M., Coombes, R.C., Krell, J., Castellano, L., miR-23b regulates cytoskeletal remodeling, motility and metastasis by directly targeting multiple transcripts. Nucleic Acids Res. 41 (2013), 5400–5412.
181. Mattiske, S., Suetani, R.J., Neilsen, P.M., Callen, D.F., The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol. Biomark. Prev. 21 (2012), 1236–1243.
182. Sun, Y., Wang, M., Lin, G., Sun, S., Li, X., Qi, J., Li, J., Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One, 7, 2012, e47003, 10.1371/journal.pone.0047003.
183. Zhang, C., Zhao, J., Deng, H., 17β-Estradiol up-regulates miR-155 expression and reduces TP53INP1 expression in MCF-7 breast cancer cells. Mol. Cell. Biochem. 379 (2013), 201–211.
184. Lu, C., Huang, X., Zhang, X., Roensch, K., Cao, Q., Nakayama, K.I., Blazar, B.R., Zeng, Y., Zhou, X., miR-221 and miR-155 regulate human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KPC1, and SOCS-1. Blood 117 (2011), 4293–4303.
185. Venkatadri, R., Muni, T., Iyer, A.K., Yakisich, J.S., Azad, N., Role of apoptosis-related miRNAs in resveratrol-induced breast cancer cell death. Cell Death Dis., 7, 2016, e2104, 10.1038/cddis.2016.6.
186. Ergün, S., Ulasli, M., Igci, Y.Z., Igci, M., Kirkbes, S., Borazan, E., Balik, A., Yumrutas, Ö, Camci, C., Cakmak, E.A., Arslan, A., Oztuzcu, S., The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer. Mol. Biol. Rep. 42 (2015), 497–505.
187. Su, C.M., Lee, W.H., Wu, A.T., Lin, Y.K., Wang, L.S., Wu, C.H., Yeh, C.T., Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition. J. Nutr. Biochem. 26 (2015), 675–685.
188. Guarino, M., Src signaling in cancer invasion. J. Cell. Physiol. 223 (2010), 14–26.
189. Hoff, P.M., Machado, K.K., Role of angiogenesis in the pathogenesis of cancer. Cancer Treat. Rev. 38 (2012), 825–833.
190. Ferrara, N., VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer. 2 (2002), 795–803.
191. Zhu, J., Yu, X., Mi, M., Genistein inhibits expression of vascular endothelial growth factor in HER-2/neu transfected human breast cancer MCF-7 cells. Chin. J. Cancer Res. 18 (2006), 83–87.
192. Niu, G., Wright, K.L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., Heller, R., Ellis, L.M., Karras, J., Bromberg, J., Pardoll, D., Jove, R., Yu, H., Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21 (2002), 2000–2008.
193. Forsythe, J.A., Jiang, B.H., Iyer, N.V., Agani, F., Leung, S.W., Koos, R.D., Semenza, G.L., Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16 (1996), 4604–4613.
194. Jung, S.T., Moon, E.S., Seo, H.Y., Kim, J.S., Kim, G.J., Kim, Y.K., Expression and significance of TGF-beta isoform and VEGF in osteosarcoma. Orthopedics 28 (2005), 755–760.
195. Mitani, T., Ito, Y., Harada, N., Nakano, Y., Inui, H., Ashida, H., Yamaji, R., Resveratrol reduces the hypoxia-induced resistance to doxorubicin in breast cancer cells. J. Nutr. Sci. Vitaminol. (Tokyo) 60 (2014), 122–128.
196. Radisky, E.S., Radisky, D.C., Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J. Mammary Gland Biol. Neoplasia 15 (2010), 201–212.
197. Magee, P.J., Allsopp, P., Samaletdin, A., Rowland, I.R., Daidzein, R-(+) equol and S-(-) equol inhibit the invasion of MDA-MB-231 breast cancer cells potentially via the down-regulation of matrix metalloproteinase-2. Eur. J. Nutr. 53 (2014), 345–350.
198. Magee, P.J., McGlynn, H., Rowland, I.R., Differential effects of isoflavones and lignans on invasiveness of MDA-MB-231 breast cancer cells in vitro. Cancer Lett. 208 (2004), 35–41.
199. Maccario, C., Savio, M., Ferraro, D., Bianchi, L., Pizzala, R., Pretali, L., Forti, L., Stivala, L.A., The resveratrol analog 4,4’-dihydroxy-trans-stilbene suppresses transformation in normal mouse fibroblasts and inhibits proliferation and invasion of human breast cancer cells. Carcinogenesis 33 (2012), 2172–2180.
200. Kim, J.E., Kim, H.S., Shin, Y.J., Lee, C.S., Won, C., Lee, S.A., Lee, J.W., Kim, Y., Kang, J.S., Ye, S.K., Chung, M.H., LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression. Exp. Mol. Med. 40 (2008), 514–522.
201. Mali, A.V., Joshi, A.A., Hegde, M.V., Kadam, S.S., Enterolactone suppresses proliferation, migration and metastasis of MDA-MB-231 breast cancer cells through inhibition of uPA induced plasmin activation and MMPs-mediated ECM remodeling, Asian Pac. J. Cancer Prev. 18 (2017), 905–915.
202. Perez, E.A., Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res. Treat. 114 (2009), 195–201.
203. Borst, P., Elferink, R.O., Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71 (2002), 537–592.
204. Xue, J.P., Wang, G., Zhao, Z.B., Wang, Q., Shi, Y., Synergistic cytotoxic effect of genistein and doxorubicin on drug-resistant human breast cancer MCF-7/Adr cells. Oncol. Rep. 32 (2014), 1647–1653.
205. Huang, F., Wu, X.N., Chen, J., Wang, W.X., Lu, Z.F., Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells. Exp. Ther. Med. 7 (2014), 1611–1616.
206. Casanova, F., Quarti, J., da Costa, D.C., Ramos, C.A., da Silva, J.L., Fialho, E., Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest. J. Cell. Biochem. 113 (2012), 2586–2596.